ZNF554 Inhibits Endometrial Cancer Progression via Regulating RBM5 and Inactivating WNT/β-Catenin Signaling Pathway

Cheng-cheng Zhu, Heng-liang Sun, Teng-fei Long, Yuan-yuan Lyu, Jiang-li Liu, Guan-tai Ni

Current Medical Science ›› 2024, Vol. 44 ›› Issue (2) : 406-418.

Current Medical Science All Journals
PDF
Current Medical Science ›› 2024, Vol. 44 ›› Issue (2) : 406-418. DOI: 10.1007/s11596-024-2845-7
Original Article

ZNF554 Inhibits Endometrial Cancer Progression via Regulating RBM5 and Inactivating WNT/β-Catenin Signaling Pathway

Author information +
History +

Abstract

Objective

Uterine corpus endometrial carcinoma (UCEC), a kind of gynecologic malignancy, poses a significant risk to women’s health. The precise mechanism underlying the development of UCEC remains elusive. Zinc finger protein 554 (ZNF554), a member of the Krüppel-associated box domain zinc finger protein superfamily, was reported to be dysregulated in various illnesses, including malignant tumors. This study aimed to examine the involvement of ZNF554 in the development of UCEC.

Methods

The expression of ZNF554 in UCEC tissues and cell lines were examined by qRT-PCR and Western blot assay. Cells with stably overexpressed or knocked-down ZNF554 were established through lentivirus infection. CCK-8, wound healing, and Transwell invasion assays were employed to assess cell proliferation, migration, and invasion. Propidium iodide (PI) staining combined with fluorescence-activated cell sorting (FACS) flow cytometer was utilized to detect cell cycle distribution. qRT-PCR and Western blotting were conducted to examine relative mRNA and protein levels. Chromatin immunoprecipitation assay and luciferase reporter assay were used to explore the regulatory role of ZNF554 in RNA binding motif 5 (RBM5).

Results

The expression of ZNF554 was found to be reduced in both UCEC samples and cell lines. Decreased expression of ZNF554 was associated with higher tumor stage, decreased overall survival, and reduced disease-free survival in UCEC. ZNF554 overexpression suppressed cell proliferation, migration, and invasion, while also inducing cell cycle arrest. In contrast, a decrease in ZNF554 expression resulted in the opposite effect. Mechanistically, ZNF554 transcriptionally regulated RBM5, leading to the deactivation of the Wingless (WNT)/β-catenin signaling pathway. Moreover, the findings from rescue studies demonstrated that the inhibition of RBM5 negated the impact of ZNF554 overexpression on β-catenin and p-glycogen synthase kinase-3β (p-GSK-3β). Similarly, the deliberate activation of RBM5 reduced the increase in β-catenin and p-GSK-3β caused by the suppression of ZNF554. In vitro experiments showed that ZNF554 overexpression-induced decreases in cell proliferation and migration were counteracted by RBM5 knockdown. Additionally, when RBM5 was overexpressed, it hindered the improvements in cell proliferation and migration caused by reducing the ZNF554 levels.

Conclusion

ZNF554 functions as a tumor suppressor in UCEC. Furthermore, ZNF554 regulates UCEC progression through the RBM5/WNT/β-catenin signaling pathway. ZNF554 shows a promise as both a prognostic biomarker and a therapeutic target for UCEC.

Keywords

zinc finger protein 554 / endometrial carcinoma / RNA binding motif 5 / Wingless/β-catenin signaling pathway

Cite this article

Download citation ▾
Cheng-cheng Zhu, Heng-liang Sun, Teng-fei Long, Yuan-yuan Lyu, Jiang-li Liu, Guan-tai Ni. ZNF554 Inhibits Endometrial Cancer Progression via Regulating RBM5 and Inactivating WNT/β-Catenin Signaling Pathway. Current Medical Science, 2024, 44(2): 406‒418 https://doi.org/10.1007/s11596-024-2845-7
This is a preview of subscription content, contact us for subscripton.

References

[1]
MakkerV, MacKayH, Ray-CoquardI, et al.. Endometrial cancer. Nat Rev Dis Primers, 2021, 7(1): 88
CrossRef Google scholar
[2]
CrosbieEJ, KitsonSJ, McAlpineJN, et al.. Endometrial cancer. Lancet, 2022, 399(10333): 1412-1428
CrossRef Google scholar
[3]
SunX, HouL, QiuC, et al.. MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer. Cell Mol Biol Lett, 2021, 26(1): 20
CrossRef Google scholar
[4]
MillerKD, NogueiraL, DevasiaT, et al.. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin, 2022, 72(5): 409-436
CrossRef Google scholar
[5]
HuvilaJ, PorsJ, ThompsonEF, et al.. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. J Pathol, 2021, 253(4): 355-365
CrossRef Google scholar
[6]
BoganiG, Ray-CoquardI, ConcinN, et al.. Endometrial carcinosarcoma. Int J Gynecol Cancer, 2023, 33(2): 147-174
CrossRef Google scholar
[7]
NeesLK, HeubleinS, SteinmacherS, et al.. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet, 2022, 306(2): 407-421
CrossRef Google scholar
[8]
MacKintoshML, CrosbieEJ. Prevention Strategies in Endometrial Carcinoma. Curr Oncol Rep, 2018, 20(12): 101
CrossRef Google scholar
[9]
HamiltonSN, TinkerAV, KwonJ, et al.. Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. J Gynecol Oncol, 2022, 33(3): e25
CrossRef Google scholar
[10]
ChenH, StricklandAL, CastrillonDH. Histopathologic diagnosis of endometrial precancers: Updates and future directions. Semin Diagn Pathol, 2022, 39(3): 137-147
CrossRef Google scholar
[11]
JamiesonA, ThompsonEF, HuvilaJ, et al.. Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. Gynecol Oncol, 2022, 165(2): 376-384
CrossRef Google scholar
[12]
KarpelHC, SlomovitzB, ColemanRL, et al.. Treatment options for molecular subtypes of endometrial cancer in 2023. Curr Opin Obstet Gynecol, 2023, 35(3): 270-278
CrossRef Google scholar
[13]
ConcinN, Matias-GuiuX, VergoteI, et al.. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer, 2021, 31(1): 12-39
CrossRef Google scholar
[14]
GuoY, HuangC, XuC, et al.. Dysfunction of ZNF554 promotes ROS-induced apoptosis and autophagy in Fetal Growth Restriction via the p62-Keap1-Nrf2 pathway. Placenta, 2023, 143: 34-44
CrossRef Google scholar
[15]
EccoG, ImbeaultM, TronoD. KRAB zinc finger proteins. Development, 2017, 144(15): 2719-2729
CrossRef Google scholar
[16]
ZhangW, ZhangyuanG, WangF, et al.. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity, 2021, 54(6): 1168-1185
CrossRef Google scholar
[17]
ItoJ, KimuraI, SoperA, et al.. Endogenous retroviruses drive KRAB zinc-finger protein family expression for tumor suppression. Sci Adv, 2020, 6(43): eabc3020
CrossRef Google scholar
[18]
JenJ, WangYC. Zinc finger proteins in cancer progression. J Biomed Sci, 2016, 23(1): 53
CrossRef Google scholar
[19]
XieG, PengZ, LiangJ, et al.. Zinc finger protein 277 is an intestinal transit-amplifying cell marker and colon cancer oncogene. JCI Insight, 2022, 7(4): e150894
CrossRef Google scholar
[20]
IyerAS, ShaikMR, RaufmanJP, et al.. The Roles of Zinc Finger Proteins in Colorectal Cancer. Int J Mol Sci, 2023, 24(12): 10249
CrossRef Google scholar
[21]
BaloghA, ReinigerL, HeteyS, et al.. Decreased Expression of ZNF554 in Gliomas is Associated with the Activation of Tumor Pathways and Shorter Patient Survival. Int J Mol Sci, 2020, 21(16): 5762
CrossRef Google scholar
[22]
BerekJS, Matias-GuiuX, CreutzbergC, et al.. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet, 2023, 162(2): 383-394
CrossRef Google scholar
[23]
YangD, MaX, XuJ, et al.. Zfx-induced upregulation of UBE2J1 facilitates endometrial cancer progression via PI3K/AKT pathway. Cancer Biol Ther, 2021, 22(3): 238-247
CrossRef Google scholar
[24]
ZhangY, WangX. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol, 2020, 13(1): 165
CrossRef Google scholar
[25]
SunM, JuJ, DingY, et al.. The signaling pathways regulated by KRAB zinc-finger proteins in cancer. Biochim Biophys Acta Rev Cancer, 2022, 1877(3): 188731
CrossRef Google scholar
[26]
ZhangX, ZhengQ, YueX, et al.. ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation. J Exp Clin Cancer Res, 2022, 41(1): 79
CrossRef Google scholar
[27]
YingY, WangM, ChenY, et al.. Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci. Proc Natl Acad Sci U S A, 2022, 119(22): e2120633119
CrossRef Google scholar
[28]
GengR, ZhengY, ZhouD, et al.. ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments. Cancer Cell Int, 2020, 20(1): 542
CrossRef Google scholar
[29]
WangL, DongL, XuJ, et al.. Hypermethylated CDO1 and ZNF454 in Cytological Specimens as Screening Biomarkers for Endometrial Cancer. Front Oncol, 2022, 12: 714663
CrossRef Google scholar
[30]
ZhangJ, ZhengZ, ZhengJ, et al.. Epigenetic-Mediated Downregulation of Zinc Finger Protein 671 (ZNF671) Predicts Poor Prognosis in Multiple Solid Tumors. Front Oncol, 2019, 9: 342
CrossRef Google scholar
[31]
AlbrechtLV, Tejeda-MuñozN, De RobertisEM. Cell Biology of Canonical Wnt Signaling. Annu Rev Cell Dev Biol, 2021, 37: 369-389
CrossRef Google scholar
[32]
KatohM, KatohM. WNT signaling and cancer stemness. Essays Biochem, 2022, 66(4): 319-331
CrossRef Google scholar
[33]
LiuJ, XiaoQ, XiaoJ, et al.. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther, 2022, 7(1): 3
CrossRef Google scholar
[34]
NusseR, CleversH. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 2017, 169(6): 985-999
CrossRef Google scholar
[35]
ParsonsMJ, TammelaT, DowLE. WNT as a Driver and Dependency in Cancer. Cancer Discov, 2021, 11(10): 2413-2429
CrossRef Google scholar
[36]
KrishnamurthyN, KurzrockR. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev, 2018, 62: 50-60
CrossRef Google scholar
[37]
NeiheiselA, KaurM, MaN, et al.. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials. Int J Cancer, 2022, 150(5): 727-740
CrossRef Google scholar
[38]
ChatterjeeA, PaulS, BishtB, et al.. Advances in targeting the WNT/β-catenin signaling pathway in cancer. Drug Discov Today, 2022, 27(1): 82-101
CrossRef Google scholar
[39]
SutherlandLC, WangK, RobinsonAG. RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol, 2010, 5(3): 294-298
CrossRef Google scholar
[40]
YuJ, JiG, ShiW, et al.. RBM5 Acts as Tumor Suppressor in Medulloblastoma through Regulating Wnt/β-Catenin Signaling. Eur Neurol, 2020, 83(3): 242-250
CrossRef Google scholar
PDF

76

Accesses

0

Citations

Detail

Sections
Recommended

/